Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

Description

As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or different method of delivery like intravenous (IV) TXA reduces the postoperative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery. The regimen that utilizes multiple doses of oral TXA will significantly minimize post-operative blood loss and transfusion requirements compared to the use of a single dose regimen. Furthermore, oral TXA will be as efficacious as intravenous delivery of TXA.

Conditions

Open Posterior Thoracolumbar Spinal Fusion Procedure

Talk to us

Study Overview

On this page

Study Details

Study overview

As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or different method of delivery like intravenous (IV) TXA reduces the postoperative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery. The regimen that utilizes multiple doses of oral TXA will significantly minimize post-operative blood loss and transfusion requirements compared to the use of a single dose regimen. Furthermore, oral TXA will be as efficacious as intravenous delivery of TXA.

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

Condition
Open Posterior Thoracolumbar Spinal Fusion Procedure
Intervention / Treatment

-

Contacts and Locations

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 6060712

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Any patient older than 18 years old
  • * Scheduled for an open posterior thoracolumbar spinal fusion procedure
  • * Allergy to TXA
  • * Acquired disturbances of color vision
  • * Refusal of blood products
  • * Pre-op use of anticoagulant therapy within five days before surgery
  • * History of arterial or venous thromboembolic disease (such as DVT, PE, CVA, TIA)
  • * Pregnancy
  • * Breastfeeding
  • * Severe ischemic heart disease \[New York Heart Association Class III or IV\]
  • * Previous myocardial infarction
  • * Severe pulmonary disease
  • * Renal impairment
  • * Hepatic failure
  • * Patients who decline to participate
  • * Intolerance or sensitivity to Vitamin C

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Rush University Medical Center,

Bryce Basques, MD, PRINCIPAL_INVESTIGATOR, Rush University Medical Center

Study Record Dates

2026-01-01